Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ALKS-2680 by Synchronicity Pharma for Type 2 Narcolepsy (Narcolepsy without Cataplexy): Likelihood of Approval
ALKS-2680 is under clinical development by Synchronicity Pharma and currently in Phase II for Type 2 Narcolepsy (Narcolepsy without Cataplexy)....
ALKS-2680 by Synchronicity Pharma for Type 1 Narcolepsy (Narcolepsy with Cataplexy): Likelihood of Approval
ALKS-2680 is under clinical development by Synchronicity Pharma and currently in Phase II for Type 1 Narcolepsy (Narcolepsy with Cataplexy)....
ALKS-2680 by Synchronicity Pharma for Idiopathic Hypersomnia (IH): Likelihood of Approval
ALKS-2680 is under clinical development by Synchronicity Pharma and currently in Phase I for Idiopathic Hypersomnia (IH). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Alkermes's ALKS-2680?
ALKS-2680 is a small molecule commercialized by Alkermes, with a leading Phase II program in Type 1 Narcolepsy (Narcolepsy with...